Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells

The Journal of Clinical Investigation
Robert S FrancoDonald L Rucknagel

Abstract

Sickle red blood cells (RBC) are subject to a number of important cellular changes and selection pressures. In this study, we validated a biotin RBC label by comparison to the standard 51Cr label, and used it to study changes that occur in sickle cells as they age. Sickle RBC had a much shorter lifespan than normal RBC, but the two labels gave equivalent results for each cell type. A variable number of sickle, but not normal, RBC disappeared from the circulation during the first few hours after reinfusion. The number of biotinylated sickle reticulocytes was decreased by 50% after 24 h and 75% after 48 h, with a gradual decrease in the amount of reticulum per cell. The labeled sickle cells exhibited major density increases during the first 4-6 d after reinfusion, with smaller changes thereafter. A small population of very light, labeled sickle RBC was essentially constant in number after the first few days. Fetal hemoglobin (HbF) content was determined in isolated biotinylated sickle RBC after reinfusion, allowing an estimate of lifespan for RBC containing HbF (F cells) and non-F cells. The lifespan of sickle biotinylated RBC lacking HbF was estimated to be approximately 2 wk, whereas F cells survived 6-8 wk.

References

Dec 28, 1978·The New England Journal of Medicine·G J DoverK Heintzelman
Apr 1, 1990·American Journal of Hematology·A ZimranE Beutler
Mar 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·T Suzuki, G L Dale
Jun 1, 1995·The Journal of Clinical Investigation·R S FrancoC H Joiner
Aug 1, 1993·Annals of Hematology·G Hoffmann-FezerS Thierfelder

❮ Previous
Next ❯

Citations

Aug 1, 2012·Journal of Pharmacokinetics and Pharmacodynamics·Rocío Lledó-GarcíaMats O Karlsson
Mar 29, 2001·Experimental Hematology·E PayenD Scherman
Feb 26, 1999·Transfusion·H CowleyJ L Miller
Jun 27, 2013·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Robert S Franco
Jul 25, 2006·Blood·Robert S FrancoDonald L Rucknagel
Jun 28, 2014·Transfusion Medicine Reviews·Donald M MockRobert S Franco
Mar 3, 2010·Expert Opinion on Drug Delivery·Vladimir R Muzykantov
Oct 18, 2005·British Journal of Haematology·Sylvia T SingerUNKNOWN E/beta Thalassaemia Study Group
Nov 26, 2008·American Journal of Hematology·Robert S Franco
Nov 2, 2012·American Journal of Hematology·Robert S FrancoRobert M Cohen
Apr 4, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Rajiv P ShresthaYossi Chait
Feb 12, 2008·Free Radical Biology & Medicine·Katherine C WoodMark T Gladwin
May 19, 2001·Blood Cells, Molecules & Diseases·C H Joiner, R S Franco
May 27, 2011·BMC Blood Disorders·Bamidele A IwalokunPhillip U Agomo
Mar 30, 2004·Diabetes Care·Robert M CohenClinton H Joiner
Feb 16, 2018·Transfusion·Djuna Z de BackRobin van Bruggen
Sep 1, 2018·Lab on a Chip·Maria Alejandra Lizarralde IragorriWassim El Nemer
Dec 25, 2004·Physiological Reviews·Virgilio L Lew, Robert M Bookchin
Feb 15, 2008·American Journal of Hematology·Christopher J LindsellRobert M Cohen
Sep 28, 2002·Blood·J David HoltzclawRobert S Franco
Apr 5, 2018·Clinical Hemorheology and Microcirculation·Carlo Brugnara
Feb 26, 2021·Current Opinion in Hematology·Eugene Khandros, Gerd A Blobel
Apr 13, 2021·Frontiers in Physiology·Alina SadafTheodosia A Kalfa
Apr 18, 2020·Molecular Therapy. Methods & Clinical Development·Christian BrendelDavid A Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.